Forte Biosciences Inc
FBRX27.590USD
-1.220-4.23%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
345.53MValor de mercado
PerdaP/L TTM
Mais detalhes de Forte Biosciences Inc Empresa
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Informações de Forte Biosciences Inc
Código da empresaFBRX
Nome da EmpresaForte Biosciences Inc
Data de listagemApr 13, 2017
CEOWagner (Paul A)
Número de funcionários14
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 13
Endereço3060 Pegasus Park Drive
CidadeDALLAS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal75247
Telefone13106186994
Sitehttps://www.fortebiorx.com/home/default.aspx
Código da empresaFBRX
Data de listagemApr 13, 2017
CEOWagner (Paul A)
Executivos da empresa Forte Biosciences Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
83.18K
+1086.00%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
41.60K
+221.00%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Mr. Richard G. (Rich) Vincent, CPA
Mr. Richard G. (Rich) Vincent, CPA
Independent Director
Independent Director
--
--
Mr. Shiv Kapoor
Mr. Shiv Kapoor
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
83.18K
+1086.00%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
41.60K
+221.00%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: qui, 22 de jan
Atualizado em: qui, 22 de jan
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Fred Alger Management, LLC
13.06%
Federated Hermes Global Investment Management Corp.
13.05%
Janus Henderson Investors
11.21%
OrbiMed Advisors, LLC
9.56%
Affinity Asset Advisors LLC
6.49%
Outro
46.64%
Investidores
Investidores
Proporção
Fred Alger Management, LLC
13.06%
Federated Hermes Global Investment Management Corp.
13.05%
Janus Henderson Investors
11.21%
OrbiMed Advisors, LLC
9.56%
Affinity Asset Advisors LLC
6.49%
Outro
46.64%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
46.65%
Hedge Fund
32.83%
Private Equity
9.56%
Investment Advisor
7.51%
Corporation
2.86%
Individual Investor
1.11%
Research Firm
0.12%
Participação acionária institucional
Atualizado em: seg, 8 de dez
Atualizado em: seg, 8 de dez
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
84
11.49M
91.73%
+522.83K
2025Q3
75
10.85M
55.60%
+222.21K
2025Q2
78
10.20M
43.87%
+4.95M
2025Q1
72
5.29M
79.85%
+32.05K
2024Q4
73
5.16M
31.17%
+3.22M
2024Q3
65
789.31K
58.51%
-26.11K
2024Q2
72
815.46K
58.79%
-11.24K
2024Q1
101
826.69K
59.45%
-38.71K
2023Q4
113
819.35K
60.39%
+5.27K
2023Q3
130
814.23K
49.33%
+164.66K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Fred Alger Management, LLC
1.64M
13.06%
+17.38K
+1.07%
Sep 30, 2025
Federated Hermes Global Investment Management Corp.
1.64M
13.05%
+156.73K
+10.60%
Sep 30, 2025
Janus Henderson Investors
1.40M
11.21%
+8.99K
+0.64%
Sep 30, 2025
OrbiMed Advisors, LLC
1.20M
9.56%
--
--
Sep 30, 2025
Affinity Asset Advisors LLC
840.00K
6.71%
+840.00K
--
Dec 17, 2025
Tybourne Capital Management (HK) Limited
786.65K
6.28%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
566.74K
4.52%
+79.82K
+16.39%
Sep 30, 2025
Cable Car Capital LLC
500.00K
3.99%
--
--
Sep 30, 2025
Sphera Funds Management Ltd.
474.31K
3.79%
-20.80K
-4.20%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Alger 35 ETF
1.35%
Texas Capital Texas Small Cap Equity Index ETF
0.06%
iShares Micro-Cap ETF
0.01%
Dimensional US Core Equity 1 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
Alger Mid Cap 40 ETF
0%
Avantis US Small Cap Equity ETF
0%
Alger 35 ETF
Proporção1.35%
Texas Capital Texas Small Cap Equity Index ETF
Proporção0.06%
iShares Micro-Cap ETF
Proporção0.01%
Dimensional US Core Equity 1 ETF
Proporção0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
Fidelity Nasdaq Composite Index ETF
Proporção0%
Alger Mid Cap 40 ETF
Proporção0%
Avantis US Small Cap Equity ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
Data
Data ex-dividendo
Tipo
Proporção
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
